- Correction
- Open access
- Published:
Correction: Targeted Inhibition of PDGFRA with avapritinib, markedly enhances lenvatinib efficacy in hepatocellular carcinoma in vitro and in vivo: clinical implications
Journal of Experimental & Clinical Cancer Research volume 44, Article number: 160 (2025)
The Original Article was published on 07 May 2025
Correction: J Exp Clin Cancer Res 44, 139 (2025)
Following the publication of the original article [1], the authors identified an identical images mistakenly used in Fig. 3A and B. The figure figure is presented below:
Incorrect Fig. 3
PDGFRA inhibitor avapritinib sensitizes HCC cells to lenvatinib treatment. (A) The effect of lenvatinib and avapritinib was tested in the colonyformation assay in SMMC-7721-LR and SNU-449-LR cells. (B) Synergistic response to the combination of lenvatinib and avapritinib in PDGFRA high C3A and SNU-398 cells and in PDGFRA low SMMC-7721 and SNU-449 cells. (C) Representative tumor images of each group of SMMC-7721-LR xenografts at the end of lenvatinib, avapritinib or combination treatment. (D) Tumor growth curves and tumor weight of each group are shown. (E) Representative H&E staining, IHC images of PDGFRA and Ki67 in subcutaneous implantation mouse model. (F) Representative tumor images of each group of PDGFRA overexpressing SMMC-7721 xenografts at the end of lenvatinib, avapritinib or combination treatment. (G) Tumor growth curve and tumor weight of each group (H) Representative H&E staining, IHC images of PDGFRA and Ki67 in subcutaneous implantation mouse model
Correct Fig. 3
PDGFRA inhibitor avapritinib sensitizes HCC cells to lenvatinib treatment. (A) The effect of lenvatinib and avapritinib was tested in the colonyformation assay in SMMC-7721-LR and SNU-449-LR cells. (B) Synergistic response to the combination of lenvatinib and avapritinib in PDGFRA high C3A and SNU-398 cells and in PDGFRA low SMMC-7721 and SNU-449 cells. (C) Representative tumor images of each group of SMMC-7721-LR xenografts at the end of lenvatinib, avapritinib or combination treatment. (D) Tumor growth curves and tumor weight of each group are shown. (E) Representative H&E staining, IHC images of PDGFRA and Ki67 in subcutaneous implantation mouse model. (F) Representative tumor images of each group of PDGFRA overexpressing SMMC-7721 xenografts at the end of lenvatinib, avapritinib or combination treatment. (G) Tumor growth curve and tumor weight of each group (H) Representative H&E staining, IHC images of PDGFRA and Ki67 in subcutaneous implantation mouse model
The correction does not compromise the validity of the conclusions and the overall content of the article. The original article [1] has been updated.
References
Zhao B, Zhou Y, Cheng N, et al. Targeted Inhibition of PDGFRA with avapritinib, markedly enhances lenvatinib efficacy in hepatocellular carcinoma in vitro and in vivo: clinical implications. J Exp Clin Cancer Res. 2025;44:139. https://doi.org/10.1186/s13046-025-03386-8.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The original article can be found online at https://doi.org/10.1186/s13046-025-03386-8.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Zhao, B., Zhou, Y., Cheng, N. et al. Correction: Targeted Inhibition of PDGFRA with avapritinib, markedly enhances lenvatinib efficacy in hepatocellular carcinoma in vitro and in vivo: clinical implications. J Exp Clin Cancer Res 44, 160 (2025). https://doi.org/10.1186/s13046-025-03423-6
Published:
DOI: https://doi.org/10.1186/s13046-025-03423-6